So the net operational cash flow after 9 months was -$2,106K.
Take away the 1 off Ikon payment of $1,407K, which leaves -$784K.
Add back the R&D rebate of $646K makes the net cash outflow -$1,400K.
Then take away the presumed annual cost reduction of $1,000K or $750K for nine months and net cash outflow is -$650K for nine months, or -$867K annualised.
On that basis with $8.5M in the bank they wouldn't need a CR for 10 years.
Last years sales were $7.1M in the 3rd Quarter as opposed to the current $5.1M
If this years sales were the same we would be $1, 450K cashflow POSITIVE.
Run your slide rule over that!
- Forums
- ASX - By Stock
- AN1
- Ann: Agreement Signed for Sale of Lyramid Limited
Ann: Agreement Signed for Sale of Lyramid Limited, page-8
-
- There are more pages in this discussion • 326 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online